Literature DB >> 30737196

A survey to assess the availability, implementation rate and remuneration of pharmacist-led cognitive services throughout Europe.

Inês Branco Soares1, Tamara L Imfeld-Isenegger2, Urska Nabergoj Makovec3, Nejc Horvat4, Mitja Kos5, Isabell Arnet6, Kurt E Hersberger7, Filipa A Costa8.   

Abstract

BACKGROUND: Pharmacist-led cognitive services (PLCS) are increasingly necessary in primary care as a response to patient-centered care. However, the implementation rate and remuneration models of PLCS are either absent or superficially described in the literature.
OBJECTIVE: The aim of this study is to review the implementation of PLCS in primary care across Europe and explore the associated third-party paid remuneration models.
METHODS: A cross-sectional study was conducted using an online survey sent to representatives of 44 European countries. The survey listed 21 PLCS and asked respondents to report the availability of the service, the rate of implementation and the existence of remuneration. To ensure credible data, data triangulation was sought using three representatives per country, representing backgrounds of community pharmacy, pharmacy practice research and health policy. Subsequently, data was validated, and consensus sought.
RESULTS: Data were collected between November 2016 and October 2017 from 34 different countries across Europe (79%). Provision of medicines' information (94.1%), generic substitution (85.3%), provision of emergency oral contraception (70.6%) and point-of-care testing (67.7%) were the services reported as the most widely disseminated in European primary care. Medication review was the most disseminated among advanced services (55.9%). Medication review, adherence support and monitoring, prescription renewal, opioid substitution and travel medicine had the highest implementation rates reported. Half of the participating countries mentioned models of remuneration, predominantly based on a fee-for-service, with less frequent reports of pay-for-performance or mixed models of remuneration.
CONCLUSIONS: The availability of PLCS is increasing and varying in scope across Europe. There is wide variation in the implementation level of services across Europe and a lack of valid data. Remuneration of PLCS is also spreading but no clear pattern was found that relates service provision to payment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Community pharmacy services [MeSH]; Europe [MeSH]; Health care [MeSH]; Health services [MeSH]; Pharmaceutical care; Pharmaceutical services [MeSH]; Remuneration [MeSH]

Year:  2019        PMID: 30737196     DOI: 10.1016/j.sapharm.2019.02.002

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  5 in total

1.  Qualitative study of medication review in Flanders, Belgium among community pharmacists and general practitioners.

Authors:  Anneleen Robberechts; Céline De Petter; Lindsey Van Loon; Silas Rydant; Stephane Steurbaut; Guido De Meyer; Hans De Loof
Journal:  Int J Clin Pharm       Date:  2021-01-23

2.  Improved adherence with Medicines Use Review service in Slovenia: a randomized controlled trial.

Authors:  Urška Nabergoj Makovec; Igor Locatelli; Mitja Kos
Journal:  BMC Health Serv Res       Date:  2021-03-22       Impact factor: 2.655

3.  Feasibility of cardiovascular risk screening in Portuguese community pharmacies.

Authors:  Anabela A Fonseca; Tácio M Lima; Margarida Castel-Branco; Isabel V Figueiredo
Journal:  Pharm Pract (Granada)       Date:  2021-05-25

4.  Development of a Platform to Align Education and Practice: Bridging Academia and the Profession in Portugal.

Authors:  Filipa Alves da Costa; Ana Paula Martins; Francisco Veiga; Isabel Ramalhinho; José Manuel Sousa Lobo; Luís Rodrigues; Luiza Granadeiro; Matilde Castro; Pedro Barata; Perpétua Gomes; Vítor Seabra; Maria Margarida Caramona
Journal:  Pharmacy (Basel)       Date:  2020-01-16

5.  Community and hospital pharmacists in Europe: encroaching on medicine?

Authors:  Livio Garattini; Anna Padula; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2020-09-13       Impact factor: 3.397

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.